Hawthorn Berry vs. Leaf & Flower: Which Fraction Fits Your EU Formulation?

Hawthorn in the European Market: Why Fraction Selection Matters

Crataegus species — commonly known as hawthorn — rank among the most commercially significant medicinal plants traded across European supply chains. Yet procurement teams and formulators frequently encounter a critical decision point early in the development cycle: should the specification call for hawthorn berry (fruit) or hawthorn leaf with flower?

This is not a trivial distinction. The two fractions differ in their active constituent profiles, standardisation benchmarks, regulatory classifications, and suitable application categories under EU law. Getting the specification right at the sourcing stage prevents costly reformulation, certificate of analysis (CoA) mismatches, and regulatory complications down the line.

---

Phytochemical Profiles: What Each Fraction Delivers

Hawthorn Berry (Crataegus monogyna / C. laevigata — Fruit)

The ripe or dried berry is primarily characterised by its oligomeric procyanidins (OPCs) and a distinct anthocyanin content responsible for its deep red pigmentation. Key constituents include:

• Oligomeric procyanidins: typically 1–3% in dried berry; primary marker for extract standardisation
• Anthocyanins (cyanidin-3-galactoside and related glycosides): contributing antioxidant activity and colour functionality
• Flavonol glycosides (hyperoside, quercetin derivatives) at lower concentrations than the leaf/flower fraction
• Triterpene acids (ursolic, oleanolic) concentrated in the pericarp

The berry fraction is particularly valued in food, beverage, and functional food applications where natural colourants, antioxidant claims, and clean-label botanical inclusion are priorities.

Hawthorn Leaf with Flower (Crataegus spp. — Herba)

This fraction — harvested at early flowering — carries a substantially different and more pharmacologically studied profile:

• Vitexin-2''-O-rhamnoside: the principal flavonoid C-glycoside; primary marker per European Pharmacopoeia (Ph. Eur. 01/2011:1432)
• Flavonoids (total): typically expressed as hyperoside equivalents; minimum 1.5% per Ph. Eur. specification
• Oligomeric procyanidins: present but at lower concentrations than the berry
• Chlorogenic acid and other hydroxycinnamic acids

This fraction is the benchmark fraction in European herbal medicine for cardiovascular applications, supported by a well-established regulatory and clinical dossier.

---

Regulatory Positioning in the EU: A Critical Differentiator

Understanding the regulatory framework is non-negotiable for compliant product development.

Traditional Herbal Medicinal Products (THMPD) — Directive 2004/24/EC

Hawthorn leaf with flower holds a positive HMPC (Committee on Herbal Medicinal Products) monograph for traditional use in the relief of temporary symptoms of mild cardiac complaints such as palpitations and rapid heart rate. The monograph specifies:

• Herba: dried leaf with flower, standardised extract (WS® 1442 at 18.75% OPCs; LI 132 at 2.2% flavonoids), or non-standardised preparations
• Oral route; defined daily dose ranges

Hawthorn berry does not hold an HMPC monograph for a medicinal indication. This makes leaf/flower the mandatory choice for any THMPD registration pathway.

Food Supplements — Regulation (EC) No 1925/2006 & National Novel Food Rules

Both fractions are widely marketed across the EU as food supplement ingredients, subject to:

• Novel Food Regulation (EU) 2015/2283 screening (neither fraction is currently on the Novel Food list; both have documented pre-1997 EU use history)
• Botanical claims remain in a regulatory grey area; health claims under Regulation (EC) No 1924/2006 are generally not authorised for hawthorn
• Member state-level positive lists (Italy, Belgium, France) should be verified for specific extract types and dosage limits

Cosmetics — Regulation (EC) No 1223/2009

Hawthorn berry extracts — particularly those standardised for OPCs and anthocyanins — find application in anti-ageing, antioxidant, and skin-conditioning cosmetic formulations. Both fractions are permitted under the Cosmetics Regulation, with no specific restrictions listed in Annex II–VI.

---

Standardisation and Quality Benchmarks for Procurement

When issuing specifications or evaluating supplier CoAs, procurement teams should align with the following benchmarks:

Hawthorn Leaf with Flower Extract

• Ph. Eur. 01/2011:1432 compliance for herbal substance
• Standardised extract: minimum 1.5% total flavonoids (as hyperoside) or minimum 18.75% OPCs (WS® 1442 equivalent)
• Heavy metals, pesticide residues, microbial limits per Ph. Eur. 2.8 and 5.19 guidelines
• Botanical identity confirmed via HPLC fingerprint and macroscopic/microscopic examination

Hawthorn Berry Extract

• No dedicated Ph. Eur. monograph for the extract; refer to ESCOP monograph or in-house specification
• Common standardisation: 1–2% OPCs (procyanidin B2 reference standard); 0.1–0.5% anthocyanins
• Solvent residue declaration per Regulation (EC) No 1881/2006 if ethanol/water extraction
• Country-of-origin documentation and harvest year traceability increasingly required by EU buyers

---

Application Matrix: Matching Fraction to Use Case

| Application Category | Recommended Fraction | Key Rationale |

|---|---|---|

| THMPD registration | Leaf & Flower | HMPC monograph; established clinical dossier |

| Food supplement (cardiovascular) | Leaf & Flower | Regulatory precedent; defined daily doses |

| Food supplement (antioxidant) | Berry | OPC/anthocyanin profile; market positioning |

| Functional food & beverage | Berry | Colour functionality; food-compatible processing |

| Cosmetics (anti-ageing) | Berry | Anthocyanin/OPC antioxidant activity |

| Nutraceutical (standardised extract) | Either | Dependent on target market and claim strategy |

---

Sourcing Considerations for B2B Buyers

Beyond regulatory alignment, quality-conscious procurement teams should evaluate suppliers on the following parameters:

• Botanical authentication: Crataegus monogyna and C. laevigata are the primary pharmacopoeial species; C. pentagyna and others may be present in bulk lots — confirm species identity
• Harvest timing: Leaf with flower must be harvested at the correct phenological stage (early flowering); berry should be harvested at full maturity — both significantly impact constituent yield
• Extraction solvent and ratio: Ethanol/water extracts at defined DER (Drug-to-Extract Ratio) are standard for pharmaceutical-grade materials
• Third-party testing: Demand independent CoAs covering identity, assay, contaminants, and microbiological parameters
• Supply chain transparency: EU buyers increasingly require full traceability from cultivation/wild collection origin to processing facility

---

Conclusion: Specification Precision Drives Formulation Success

Hawthorn is not a commodity to be sourced generically. The choice between berry and leaf-with-flower determines your regulatory pathway, your standardisation framework, and ultimately your product's market positioning. Leaf with flower remains the evidence-based, pharmacopoeially recognised fraction for cardiovascular health applications in the EU medicinal space. Berry extract offers distinct advantages in food, beverage, and cosmetic contexts where colour, antioxidant functionality, and clean-label appeal are the brief.

At TANDOR, buyers can evaluate certified botanical raw materials from verified suppliers across both fractions, with full documentation support including Ph. Eur. compliance statements, origin certificates, and standardised CoA formats — enabling procurement decisions grounded in regulatory confidence and quality assurance.